{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:01:29Z","timestamp":1781067689135,"version":"3.54.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory activation may contribute to adverse remodeling and recurrent cardiovascular events after myocardial infarction (MI), but its prognostic value in patients with heart failure with preserved ejection fraction (HFpEF) remains uncertain. This study evaluated whether the Inflammatory Burden Index (IBI) was associated with 1-year major adverse cardiovascular events (MACE) in patients with HFpEF and documented MI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>In this single-centre retrospective cohort study, 625 patients hospitalized at Fuyang People's Hospital from January 2018 to December 2023 were screened. After 33 patients with incomplete follow-up or unavailable baseline data were excluded, 592 patients were included. IBI was calculated as C-reactive protein multiplied by the neutrophil-to-lymphocyte ratio. The Youden-derived IBI cutoff of 7.70 was used only for descriptive grouping and sensitivity analysis. The primary Cox model treated log-transformed IBI (logIBI) as a continuous predictor and adjusted for age, sex, hypertension, diabetes mellitus, LDL-C and soluble ST2. Discrimination, calibration and clinical usefulness were assessed using the C-index, 365-day AUC, Brier score, calibration slope, Hosmer-Lemeshow test and decision curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During 1-year follow-up, 74 patients experienced MACE (12.5%). Higher logIBI was independently associated with 1-year MACE (HR 1.828, 95% CI 1.529\u20132.186,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). In the sensitivity model, high IBI was also associated with increased MACE risk (HR 4.126, 95% CI 2.512\u20136.776,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Adding logIBI improved the 365-day AUC from 0.790 to 0.832 and increased the C-index from 0.776 to 0.817. The expanded model showed generally acceptable calibration, with a Brier score of 0.075, calibration slope of 0.938 and Hosmer-Lemeshow\n                      <jats:italic>P<\/jats:italic>\n                      value of 0.202. Decision curve analysis suggested higher net benefit after adding logIBI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with HFpEF and documented MI, higher logIBI was independently associated with 1-year MACE and improved risk discrimination when added to a base clinical model. IBI may provide a practical admission-level measure of residual inflammatory burden, but external validation and prospective assessment are needed before clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1831654","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:29:59Z","timestamp":1781065799000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of the inflammatory burden index with 1-year major adverse cardiovascular events in patients with HFpEF after myocardial infarction: a single-center retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoyan","family":"Yin","sequence":"first","affiliation":[{"name":"Fuyang People's Hospital, Bengbu Medical University Affiliated Fuyang Hospital","place":["Fuyang, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Chen","sequence":"additional","affiliation":[{"name":"Fuyang People's Hospital, Anhui Medical University Affiliated Fuyang People's Hospital","place":["Fuyang, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshi","family":"Liu","sequence":"additional","affiliation":[{"name":"Fuyang People's Hospital, Anhui Medical University Affiliated Fuyang People's Hospital","place":["Fuyang, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ren","sequence":"additional","affiliation":[{"name":"Fuyang People's Hospital, Bengbu Medical University Affiliated Fuyang Hospital","place":["Fuyang, Anhui, China"]},{"name":"Fuyang People's Hospital, Anhui Medical University Affiliated Fuyang People's Hospital","place":["Fuyang, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.11909\/j.issn.1671-5411.2020.07.007","article-title":"The prognostic role of high-sensitivity C-reactive protein in patients with acute myocardial infarction","volume":"17","author":"Polyakova","year":"2020","journal-title":"J Geriatr Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12933-020-01157-7","article-title":"Prognostic impact of admission high-sensitivity C-reactive protein in acute myocardial infarction patients with and without diabetes mellitus","volume":"19","author":"Lucci","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12933-023-01932-2","article-title":"Prognostic value of high-sensitivity C-reactive protein in patients undergoing percutaneous coronary intervention with different glycemic metabolism status","volume":"22","author":"Li","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"ehaf784.3779","DOI":"10.1093\/eurheartj\/ehaf784.3779","article-title":"High-sensitivity C-reactive protein predicts post-percutaneous coronary intervention cardiovascular risk with BMI threshold effect: evidence from a prospective registry study","volume":"46","author":"Chen","year":"2025","journal-title":"Eur Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e39761","DOI":"10.1016\/j.heliyon.2024.e39761","article-title":"The neutrophil-to-lymphocyte ratio is associated with in-hospital heart failure in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"10","author":"Hou","year":"2024","journal-title":"Heliyon"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/jrms.jrms_485_22","article-title":"The predictive value of neutrophil-lymphocyte ratio combined with the global registry of acute coronary events score for inhospital adverse cardiovascular events in patients with acute ST-elevation myocardial infarction","volume":"29","author":"Fang","year":"2024","journal-title":"J Res Med Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e38692","DOI":"10.1097\/MD.0000000000038692","article-title":"Neutrophil to lymphocyte ratio as a prognostic marker for cardiovascular outcomes in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"103","author":"Ul Hussain","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijcard.2020.01.039","article-title":"Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction","volume":"304","author":"Song","year":"2020","journal-title":"Int J Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e009446","DOI":"10.1161\/CIRCHEARTFAILURE.121.009446","article-title":"The association of protein biomarkers with incident heart failure with preserved and reduced ejection fraction","volume":"16","author":"Takvorian","year":"2023","journal-title":"Circ Heart Fail"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9322460","DOI":"10.1155\/2022\/9322460","article-title":"Predictive value of soluble growth stimulator gene 2 protein for coronary slow flow\/no-reflow in ST-elevation myocardial infarction patients receiving percutaneous coronary intervention","volume":"2022","author":"Chang","year":"2022","journal-title":"J Interv Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12872-025-04488-z","article-title":"Short-term predictive value of sST2 in patients with STEMI following primary PCI: a prospective observational study","volume":"25","author":"Huang","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3000605251406969","DOI":"10.1177\/03000605251406969","article-title":"The prognostic value of circulating soluble ST2 in patients with chronic heart failure","volume":"54","author":"Zhang","year":"2026","journal-title":"J Int Med Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"643358","DOI":"10.3389\/fcvm.2021.643358","article-title":"Estimated glomerular filtration rate is associated with an increased risk of death in heart failure patients with preserved ejection fraction","volume":"8","author":"Chen","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamacardio.2023.4664","article-title":"Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial","volume":"9","author":"Mc Causland","year":"2024","journal-title":"JAMA Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2215\/CJN.0000000000000519","article-title":"Acute myocardial infarction and chronic kidney disease: a nationwide cohort study on management and outcomes from 2010 to 2022","volume":"19","author":"Freese Ballegaard","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1253\/circj.CJ-20-1115","article-title":"Impact of chronic kidney disease on in-hospital and 3-year clinical outcomes in patients with acute myocardial infarction treated by contemporary percutaneous coronary intervention and optimal medical therapy: insights from the J-MINUET study","volume":"85","author":"Hashimoto","year":"2021","journal-title":"Circ J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"25034","DOI":"10.1038\/s41598-025-09574-2","article-title":"Inflammatory burden index predicts long-term mortality in a nationally representative population from NHANES","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0325287","DOI":"10.1371\/journal.pone.0325287","article-title":"Association between inflammatory burden index and prognosis in patients with coronary heart disease: a retrospective study","volume":"20","author":"Lu","year":"2025","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2147\/TCRM.S518889","article-title":"Inflammatory burden Index associated with recurrence of atrial fibrillation after radiofrequency catheter ablation","volume":"21","author":"Peng","year":"2025","journal-title":"Ther Clin Risk Manag"},{"key":"B27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s13019-025-03644-y","article-title":"Correlation of inflammatory burden index with 30-day readmission rates in patients post-elective percutaneous coronary intervention","volume":"20","author":"Yang","year":"2025","journal-title":"J Cardiothorac Surg"},{"key":"B28","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12872-025-04781-x","article-title":"Association between inflammatory burden index and risk of heart failure. Evidence from NHANES 2003\u20132017","volume":"25","author":"Yun","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2147\/JIR.S417900","article-title":"Association between inflammatory burden index and unfavorable prognosis after endovascular thrombectomy in acute ischemic stroke","volume":"16","author":"Du","year":"2023","journal-title":"J Inflamm Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3000605251381579","DOI":"10.1177\/03000605251381579","article-title":"Association between the C-reactive protein-albumin-lymphocyte index and severity of acute coronary syndrome: a retrospective study","volume":"53","author":"Wu","year":"2025","journal-title":"J Int Med Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12872-025-04522-0","article-title":"Lymphocyte to C-reactive protein ratio predicts the risk of contrast-induced acute kidney injury in STEMI patients undergoing percutaneous coronary intervention","volume":"25","author":"Xiang","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"B32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1089\/sur.2024.288","article-title":"Association between systemic immune-inflammation index and outcomes of acute myocardial infarction: a systematic review and meta-analysis","volume":"26","author":"Sun","year":"2025","journal-title":"Surg Infect (Larchmt)"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1831654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:30:03Z","timestamp":1781065803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1831654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":32,"alternative-id":["10.3389\/fcvm.2026.1831654"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1831654","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1831654"}}